First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation (LON:FBT – Get Free Report) shares shot up 0.5% during mid-day trading on Tuesday . The company traded as high as GBX 1,484.02 ($18.75) and last traded at GBX 1,483.50 ($18.75). 180 shares were traded during trading, a decline of 86% from the average session volume of 1,303 shares. The stock had previously closed at GBX 1,475.40 ($18.65).
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation Stock Up 0.6 %
The company has a debt-to-equity ratio of 0.04, a current ratio of 9.42 and a quick ratio of 9.27. The company has a market capitalization of £4.42 billion and a P/E ratio of -1,359.64. The stock has a 50-day moving average price of GBX 1,457.47 and a 200-day moving average price of GBX 1,444.17.
First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation Company Profile
Forbidden Technologies plc develops and owns cloud-based video technology in the United Kingdom, North America, and internationally. It offers Forscene, a cloud based video post-production and publishing platform with various applications, such as editing, adding closed caption, graphics, metadata fast, remote viewing, collaboration, and publishing content.
Recommended Stories
- Five stocks we like better than First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation
- Comparing and Trading High PE Ratio Stocks
- 3 Value Stocks Too Small For Buffett’s Portfolio
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Foot Locker Builds Up Another Head of Steam; Gains Imminent
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Disney Stock Catches 3 Upgrades In a Single Week
Receive News & Ratings for First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation and related companies with MarketBeat.com's FREE daily email newsletter.